ImmunoBridge empowers community oncologists to deliver cutting-edge CAR-T cell therapies, bringing the latest advancements in cancer treatment directly to patients. As the nation’s first independent full-service CAR-T provider, we partner with community oncology practices, providing a best-in-class framework encompassing expert clinical teams, streamlined patient navigation, comprehensive educational resources, and access to innovative clinical trials. Our mission is to ensure accessible, patient-centric, and cost-effective advanced cancer care for all.
ImmunoBridge was founded on the belief that access to immunotherapies like CAR-T shouldn’t be limited by location or resources. We understand the critical role community oncologist play in patient care and are dedicated to partnering with them in offering the most advanced CAR-T treatments available.
As the first independent full-service CAR-T center, we’ve developed a unique model that removes the complexities and barriers associated with implementing this new type of therapy. Our team comprises leading experts in oncology, immunotherapy, and patient care, driven by a shared commitment to improving patient outcomes.
What we do?
ImmunoBridge provide patients with advanced CAR-T cell therapy in a comfortable, outpatient setting. Partnering closely with community oncology practices and hospitals, we ensure a seamless, coordinated treatment journey that aligns with the highest standards of care that doctors and their patients expect.
Standardized Protocols & Training: We provide best-in-class treatment protocols, REMs management, comprehensive staff training (physicians, nurses, administrative staff), and ongoing support to ensure consistent, high-quality care.
Patient Education & Navigation: We develop and deliver educational resources for patients and their families, guiding them through every step of the CAR-T journey, from initial consultation to post-treatment follow-up. We also offer dedicated patient navigation support to address their questions and concerns.
Apheresis & Chemotherapy Management: We manage the apheresis process (collecting the patient’s immune cells) and administer the necessary chemotherapy prior to CAR-T cell infusion, adhering to established protocols.
Billing & Reimbursement Support: We handle the complexities of CAR-T billing and reimbursement, working to maximize patient access and minimize financial burdens.
Physician Oversight & Treatment: Importantly, the patient’s own oncologist at the partner practice retains full oversight of the patient’s care throughout the CAR-T process. ImmunoBridge provides the infrastructure and support, but the physician remains at the center of the patient’s treatment plan.
Pharmaceutical Partnership: ImmunoBridge has established strategic partnerships and approved REMs protocols with top pharmaceutical companies, ensuring access to high-quality CAR-T therapies and related resources.
Clinical Trials: Immunobridge is equipped to facilitate CAR-T and CAR-NK clinical trials, expanding treatment options for patients and providing opportunities for providers to participate in upcoming trials.
What we do?
ImmunoBridge provide patients with advanced CAR-T cell therapy in a comfortable, outpatient setting. Partnering closely with community oncology practices and hospitals, we ensure a seamless, coordinated treatment journey that aligns with the highest standards of care that doctors and their patients expect.
What We Do?
ImmunoBridge provide patients with advanced CAR-T cell therapy in a comfortable, outpatient setting. Partnering closely with community oncology practices and hospitals, we ensure a seamless, coordinated treatment journey that aligns with the highest standards of care that doctors and their patients expect.
Standardized Protocols & Training: We provide best-in-class treatment protocols, REMs management, comprehensive staff training (physicians, nurses, administrative staff), and ongoing support to ensure consistent, high-quality care.
Patient Education & Navigation: We develop and deliver educational resources for patients and their families, guiding them through every step of the CAR-T journey, from initial consultation to post-treatment follow-up. We also offer dedicated patient navigation support to address their questions and concerns.
Apheresis & Chemotherapy Management: We manage the apheresis process (collecting the patient's immune cells) and administer the necessary chemotherapy prior to CAR-T cell infusion, adhering to established protocols.
Billing & Reimbursement Support: We handle the complexities of CAR-T billing and reimbursement, working to maximize patient access and minimize financial burdens.
Physician Oversight & Treatment: Importantly, the patient's own oncologist at the partner practice retains full oversight of the patient's care throughout the CAR-T process. ImmunoBridge provides the infrastructure and support, but the physician remains at the center of the patient's treatment plan.
Pharmaceutical Partnership: ImmunoBridge has established strategic partnerships and approved REMs protocols with top pharmaceutical companies, ensuring access to high-quality CAR-T therapies and related resources.
Clinical Trials: : Immunobridge is equipped to facilitate CAR-T and CAR-NK clinical trials, expanding treatment options for patients and providing opportunities for providers to participate in upcoming trials.
A Seamless CAR-T Therapy Journey for Your Patients
Cell Storage Advanced cell storage for CAR-T viability
Lymphodepleting Chemotherapy Preparation for optimal CAR-T integration
Leukapheresis Cell collection for personalized therapy
Patient Monitoring real-time patient monitoring, in-house & remote
Post-Treatment Transition Once successfully treated, the patient returns to your care
Our Focused Treatments
Approved CAR-T Cancer Types:
- Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Multiple Myeloma
- B-cell ALL
CAR T Therapy
CAR-T therapy represents a groundbreaking approach in cancer treatment. We specialize in CAR-T treatments targeting B-cell Maturation Antigen (BCMA), offering patients the potential for deep and durable responses. View More →
BiTES
Our expertise extends to bispecific antibodies and Bispecific T Cell Engaging Antibodies (BiTEs), which provide a promising alternative to CAR-T therapy. These "off the shelf" antibody moieties create a synapse between cancer cells and cytotoxic T cells. View More →
Neoantigen Vaccines
We believe that individualized neoantigen vaccines hold the key to transforming cancer care. By identifying neoantigens in tumors and designing tailored combination treatments, we aim to reduce the lethality of cancers that are otherwise non-responsive to traditional treatments. View More →